COMPANY PROFILE

Zymedi

Explore full profile

Zymedi makes drugs into the formula for "4T" for safety, acceptance, clarity and selection

Incheon, South KoreaFounded 2019Biotech & Life Sciences

Valuation $100–250M Last recorded · 2021

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Zymedi

Zymedi is a biotechnology company focused on developing novel therapeutics to address unmet clinical needs in diseases with no current cure. Leveraging a deep understanding of Aminoacyl tRNA Synthetase (ARS) biology, Zymedi explores multiple therapeutic routes to discover and develop drugs with solid scientific rationale. The company primarily serves the healthcare and pharmaceutical sectors, targeting complex diseases that lack effective treatments. Operating in the global biotech market, Zymedi's business model revolves around research and development (R&D) of innovative drugs, which are then licensed to pharmaceutical companies or brought to market through partnerships. Revenue is generated through licensing agreements, milestone payments, and royalties from drug sales.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2019
Headquarters: Incheon, South Korea
Employees: 11
Open positions: None listed
Dealroom signal: 40.9/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
GRANTOther financing	Jan 2025	$0	—	Undisclosed	↗
SERIES A✓Equity / VC	Aug 2021	$27M	$108M	Undisclosed	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Zymedi website traffic

Latest recorded traffic for Zymedi is 4.6K monthly website visits, up 48.4% over the last three months. Zymedi's team grew 10% over the past year.

Latest monthly visits4.6K 3-month web change+48.4% 1-year team growth+10%

Monthly website visitsOct 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
TTTeitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases	Aarhus, Denmark	Operational	25	$31M	$123M
NENeurOpResearch company developing different drug compounds	Atlanta, United States	Operational
KPKringle PharmaKringle Pharma is a late clinical-stage biopharmaceutical company focused on research and development of regenerative medicines	Toyonaka, Japan	Operational
TBTAGCyx BiotechnologiesCreating candidate compounds for high-performance nucleic acid drugs with high affinity and specificity for target molecules using our proprietary nucleic acid basic technology	Tokyo, Japan	Acquired
ATAsgard TherapeuticsSpin-off company from Lund University focusing on developing cancer immunotherapies based on cell fate reprogramming	Lund Municipality, Sweden	Operational
ASAstronauTxSmall-molecule therapeutics targeting astrocytes for neurodegenerative diseases	Reading, United Kingdom	Operational
EXExonateTopical small-molecule therapeutics for retinal vascular diseases	Cambridge, United Kingdom	Operational
RTRewind TherapeuticsFirst-in-class remyelinating therapies for myelin-related diseases	Belgium, United States	Operational